Special Issue "Antiphospholipid Antibodies"
Deadline for manuscript submissions: 31 December 2023 | Viewed by 232
Interests: autoimmunity; antiphospholipid syndrome; antiphospholipid antibodies; autoimmune diseases
Interests: systemic lupus erythematosus; rheumatic diseases; autoimmunity; clinical rheumatology; autoimmune disorders
Special Issues, Collections and Topics in MDPI journals
Antiphospholipid antibodies (aPLs) are those that are directed against phospholipids—the phosphorus-containing fats that make up our cell membranes. Certain blood proteins interact with phospholipids and the immune complexes produced when proteins and phospholipids interact. The lupus anticoagulant (LA), anticardiolipin antibody (aCL) and anti-beta-2-glycoprotein 1 (anti-β2GPI) antibodies are the three aPLs that are most frequently mentioned which are also known as the classic aPLs. There are a number of non-classic aPLs such as antiphosphatidylserine, antiphosphatidylinositol, antiphosphatidicacid, antiphosphatidylethanolamine, antiphosphatidylglycerol, anti-annexin V or antiprothrombin antibodies. To date, strong evidence indicates the causative factor of some of the aPLs in developing thrombotic events and pregnancy complications (i.e., recurrent miscarriage). In addition, aPLs have been found to be significantly present in patients exhibiting autoimmune or rheumatic diseases like antiphospholipid syndrome, systemic lupus erythematosus or Behcet's disease, cancers (i.e., solid or haematologic malignancies), and neurologic conditions like migraine, dementia or epilepsy. This may indicate that the role of aPLs goes far beyond the biomarker role only and may be directly involved in the pathogenesis of various autoimmune disorders. An example of this is that during the COVID-19 pandemic, significantly higher titres of aPLs were observed in patients with COVID-19.
In this Special Issue, we would be inviting researchers to submit their original research or review articles on the aPLs as a mediator or diagnostic tool for different diseases or conditions. We especially appreciate papers on aPLs as potential novel biomarkers in different diseases, aPLs-mediated pathogenesis in different conditions, novel laboratory testing and optimisation of aPLs detection, and clinical, epidemiological or basic-science-oriented investigations on aPLs.
Dr. Md Asiful Islam
Prof. Dr. Przemysław Kotyla
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- antiphospholipid antibodies
- lupus anticoagulant
- anticardiolipin antibody
- anti-β2-glycoprotein I antibody
- antiphospholipid syndrome
- autoimmune diseases